Levosulpiride (Lesuride) Pharmacology, Dosing, and Infusion Suitability
Levosulpiride is a selective dopamine D2 receptor antagonist and prokinetic agent that can be administered orally, intramuscularly, or intravenously, with dosing typically ranging from 25-75 mg daily depending on indication and route, though prolonged infusion has been studied primarily with the related compound lisuride rather than levosulpiride itself.
Pharmacology
Levosulpiride is the levo-enantiomer of sulpiride, functioning as a selective dopamine D2 receptor antagonist. The drug exhibits prokinetic properties and has been used for gastrointestinal disorders and neuropsychiatric conditions 1. In functional dyspepsia, levosulpiride 25 mg three times daily may be efficacious as second-line treatment 1.
Key Pharmacokinetic Properties
- Oral bioavailability: Poor at approximately 23.4% in humans 2
- Intramuscular bioavailability: Excellent at 96.8% 2
- Time to steady state:
- Oral administration: Day 4 with accumulation index of 1.8
- IM administration: Day 2 with accumulation index of 1.3 2
- Absorption: Significantly slower via oral route compared to IM, which may delay clinical efficacy 2
Dosing Regimens
Standard Dosing by Route
Oral Administration:
- Starting dose: 25 mg three times daily 1
- Range studied: 25-100 mg doses 2
- Linear pharmacokinetics demonstrated over 25-100 mg dose range 2
Intramuscular Administration:
- Dose range: 25-75 mg 2
- Linear pharmacokinetics over this range 2
- Preferred over oral route when rapid onset needed due to superior bioavailability
Intravenous Administration:
- Limited human data available
- Studied primarily in research settings 2
Important Dosing Considerations
- No sex-based adjustment needed: Pharmacokinetic properties show no significant differences between males and females 2
- Renal impairment: Use with caution; dose adjustment likely needed though specific guidelines not established in provided evidence
- Hepatic impairment: Caution advised 1
- Elderly/frail patients: Consider lower starting doses 3
Suitability for Prolonged Infusion
Critical Distinction: Lisuride vs Levosulpiride
The evidence for prolonged infusion primarily involves lisuride (a different dopamine agonist), not levosulpiride:
Lisuride Infusion Data:
- Subcutaneous infusion doses: 0.24-2.4 mg/day (41-104 mcg/hour) 4, 5, 6, 7
- Intravenous infusion: 0.6-2.4 mg/day 4
- Duration: Successfully used for 5-36 months in some patients 6
- Low-dose regimens (0.24-0.42 mg/day) showed better tolerability with mean treatment duration of 27 months 7
Levosulpiride-Specific Infusion Considerations
Limited evidence exists for levosulpiride continuous infusion in humans. The available data suggests:
- Tolerability concerns: More than half (54.8%) of subjects experienced adverse events including constipation, diarrhea, drowsiness, skin rash, and extrapyramidal reactions on multiple dosing 2
- Stability data: Post-dilution stability information is limited and requires further examination 8
- No established protocols: Unlike lisuride, there are no validated continuous infusion protocols for levosulpiride in clinical practice
Adverse Effects Limiting Long-Term Infusion
Common side effects that may limit prolonged use:
- Extrapyramidal symptoms (EPSEs) 3, 9
- Subcutaneous nodules at injection sites (with SC infusion) 5
- Psychiatric disturbances including acute psychosis 5
- Nausea and vomiting 4
- Hemorrhagic complications (mild) 5
Clinical Recommendations
For standard clinical use, levosulpiride should be administered as:
- First choice: IM route at 25-75 mg doses when parenteral administration needed (superior bioavailability)
- Oral route: 25 mg three times daily for functional dyspepsia, accepting delayed onset due to poor bioavailability
- Avoid oral route in veterinary species: Bioavailability extremely low (4.73% in goats) 10
For prolonged infusion needs, the evidence does not support routine use of levosulpiride via continuous infusion. If continuous dopaminergic modulation is required, consider alternative agents with established infusion protocols.
Key Pitfalls to Avoid
- Do not assume oral and parenteral levosulpiride are interchangeable—the 4-fold difference in bioavailability requires dose adjustment
- Do not extrapolate lisuride infusion data directly to levosulpiride—these are different compounds
- Monitor closely for extrapyramidal symptoms, particularly with prolonged use or higher doses
- Be aware that steady-state takes 4 days with oral dosing versus 2 days with IM administration